Johnson & Johnson
NYSE-JNJ
Company Overview
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Name
Johnson & Johnson
CEO
Mr. Joaquin Duato
Website
www.jnj.com
Sector
Pharmaceuticals
Year Founded
1886
Profile
Market Cap
$401.99B
EV
$418B
Shares Out
2,407.24M
Revenue
$86.58B
Employees
131,900
Margins
Gross
69.43%
EBITDA
35.85%
Operating
27.9%
Pre-Tax
22.53%
Net
43.91%
FCF
22.91%
Returns (5Yr Avg)
ROA
11.91%
ROTA
97.91%
ROE
30.03%
ROCE
17.33%
ROIC
15.91%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$171.32
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$25.48B
Net Debt
$16.02B
Debt/Equity
0.58
EBIT/Interest
31.45
Growth (CAGR)
Rev 3Yr
-0.99%
Rev 5Yr
1.26%
Rev 10Yr
1.67%
Dil EPS 3Yr
32.44%
Dil EPS 5Yr
20.73%
Dil EPS 10Yr
11.07%
Rev Fwd 2Yr
3.43%
EBITDA Fwd 2Yr
4.38%
EPS Fwd 2Yr
3.89%
EPS LT Growth Est
3.95%
Dividends
Yield
—
Payout
71.53%
DPS
$4.81
DPS Growth 3Yr
5.55%
DPS Growth 5Yr
5.67%
DPS Growth 10Yr
6.02%
DPS Growth Fwd 2Yr
4.52%